Abstract
McArdle disease (also known as glycogen storage disease type V) is a pure myopathy caused by an inherited deficit of myophosphorylase, the skeletal muscle isoform of the enzyme glycogen phosphorylase. The disease exhibits clinical heterogeneity, but patients typically experience exercise intolerance, that is, reversible, acute crises (early fatigue and contractures, sometimes with rhabdomyolysis and myoglobinuria) triggered by static muscle contractions (e.g. lifting weights) or dynamic exercise (e.g. climbing stairs or running). In this Review, we discuss the main features of McArdle disease, with the aim of providing neurologists with up-to-date, useful information to assist their patients. The topics covered include diagnostic tools—for example, molecular genetic diagnosis, the classic ischemic forearm test and the so-called 'second wind' phenomenon—and current therapeutic options—for example, a carbohydrate-rich diet and carbohydrate ingestion shortly before strenuous exercise, in combination with medically supervised aerobic training of low to moderate intensity.
Key Points
-
McArdle disease is a pure myopathy caused by an inherited deficit of the skeletal muscle isoform of glycogen phosphorylase
-
The main problem in this condition is exercise intolerance, with most patients experiencing acute 'muscle crises' after static or intense dynamic exercise
-
Crises appear in the form of early muscle fatigue and contractures, sometimes with marked muscle breakdown (rhabdomyolysis) and myoglobinuria
-
Until a definitive cure is found, patients can benefit from adopting a diet rich in complex carbohydrates and ingesting simple carbohydrates before strenuous exercise
-
Carefully supervised, regular, aerobic exercise of low to moderate intensity is a safe, recommended therapeutic option, but exercises that involve heavy static contractions or induce severe myalgia should be avoided
Similar content being viewed by others
References
Haller RG (2000) Treatment of McArdle disease. Arch Neurol 57: 923–924
McArdle B (1951) Myopathy due to a defect in muscle glycogen breakdown. Clin Sci 10: 13–33
Andreu AL et al. (2007) McArdle disease: molecular genetic update. Acta Myol 26: 53–57
DiMauro S (2007) Muscle glycogenoses: an overview. Acta Myol 26: 35–41
Isackson PJ et al. (2005) A novel mutation in the PYGM gene in a family with pseudo-dominant transmission of McArdle disease. Mol Genet Metab 85: 239–242
Tsujino S et al. (1993) Molecular genetic heterogeneity of myophosphorylase deficiency (McArdle's disease). N Engl J Med 329: 241–245
DiMauro S et al. (2002) Myophosphorylase deficiency (glycogenosis type V; McArdle disease). Curr Mol Med 2: 189–196
Vissing J and Haller RG (2003) The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. N Engl J Med 349: 2503–2509
Zange J et al. (2003) Breakdown of adenine nucleotide pool in fatiguing skeletal muscle in McArdle's disease: a noninvasive 31P-MRS and EMG study. Muscle Nerve 27: 728–736
Lewis SF and Haller RG (1986) The pathophysiology of McArdle's disease: clues to regulation in exercise and fatigue. J Appl Physiol 61: 391–401
Haller et al. (1998) Reduced levels of skeletal muscle Na+K+-ATPase in McArdle disease. Neurology 50: 37–40
Martinuzzi A et al. (2003) Phenotype modulators in myophosphorylase deficiency. Ann Neurol 53: 497–502
Rubio JC et al. (2007) Genotype modulators of clinical severity in McArdle disease. Neurosci Lett 422: 217–222
Maté-Muñoz JL et al. (2007) Favorable responses to acute and chronic exercise in McArdle patients. Clin J Sport Med 17: 297–303
Paradas C et al. (2005) Variable presentation of the clinical phenotype of McArdle's disease in a kindred harbouring a novel compound genotype in the muscle glycogen phosphorylase gene. Neurosci Lett 31: 28–31
Voduc N et al. (2004) McArdle's disease presenting as unexplained dyspnea in a young woman. Can Respir J 11: 163–167
Williams AG et al. (2000) The ACE gene and muscle performance. Nature 403: 614
Gómez-Gallego F et al. (2008) The I allele of the ACE gene is associated with improved exercise capacity in women with McArdle disease. Br J Sports Med 42: 134–140
Tsujino S et al. (1995) Double trouble: combined myophosphorylase and AMP deaminase deficiency in a child homozygous for nonsense mutations at both loci. Neuromuscul Disord 15: 263–266
Rubio JC et al. (2008) AMPD1 genotypes and exercise capacity in McArdle patients. Int J Sports Med 29: 331–335
Pérez M et al. (2007) Exercise capacity in a child with McArdle disease. J Child Neurol 22: 880–882
DiMauro S and Hartlage PL (1978) Fatal infantile form of muscle phosphorylase deficiency. Neurology 28: 1124–1129
Pérez M et al. (2006) Exercise capacity in a 78 year old patient with McArdle's disease: it is never too late to start exercising. Br J Sports Med 40: 725–726
DiMauro S and Tsujino S (1995) Nonlysosomal glycogenoses. In Myology, 1554–1556 (Eds Engel AG and Franzini-Armstrong C) New York: McGraw-Hill
Jinnai K et al. (1993) Glycogenosis type V (McArdle's disease) with hyperuricemia: a case report and clinical investigation. Eur Neurol 33: 204–207
Mineo I et al. (1987) Myogenic hyperuricemia: a common pathophysiologic feature of glycogenosis types III, V, and VII. N Engl J Med 317: 75–80
Bollig G et al. (2005) McArdle's disease and anaesthesia: case reports: review of potential problems and association with malignant hyperthermia. Acta Anaesthesiol Scand 49: 1077–1083
Lorenzoni PJ et al. (2007) McArdle disease with rhabdomyolysis induced by rosuvastatin: case report [Portuguese]. Arq Neuropsiquiatr 65: 834–837
Pearson C et al. (1961) A metabolic myopathy due to absence of muscle phosphorylase. Am J Med 30: 502–517
Haller RG and Vissing J (2002) Spontaneous 'second wind' and glucose-induced second 'second wind' in McArdle disease: oxidative mechanisms. Arch Neurol 59: 1395–1402
Haller RG and Vissing J (2004) No spontaneous second wind in muscle phosphofructokinase deficiency. Neurology 62: 82–86
Haller RG and Lewis SF (1991) Glucose-induced exertional fatigue in muscle phosphofructokinase deficiency. N Engl J Med 324: 364–369
Vissing J and Haller RG (2003) A diagnostic cycle test for McArdle's disease. Ann Neurol 54: 539–542
Ørngreen MC et al. (2008) Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase deficiency. Neurology 70: 1872–1873
Vissing J et al. (2005) Effects of fuels on exercise capacity in muscle phosphoglycerate mutase deficiency. Arch Neurol 62: 1440–1444
Deschauer M et al. (2005) Muscle carnitine palmitoyltransferase II deficiency: clinical and molecular genetic features and diagnostic aspects. Arch Neurol 62: 37–41
Lindner A et al. (2001). Acute compartment syndrome after forearm ischemic work test in a patient with McArdle's disease. Neurology 56: 1779–1780
Kazemi-Esfarjani P et al. (2002) A nonischemic forearm exercise test for McArdle disease. Ann Neurol 52: 153–159
Bergström J (1975) Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand J Clin Lab Invest 35: 609–616
Nogales-Gadea G et al. (2007) Molecular genetics of McArdle's disease. Curr Neurol Neurosci Rep 7: 84–92
Bruno C et al. (2006) McArdle disease: the mutation spectrum of PYGM in a large Italian cohort. Hum Mutat 27: 718
Lebo RV et al. (1984) High-resolution chromosome sorting and DNA spot-blot analysis assign McArdle's syndrome to chromosome 11. Science 225: 57–59
Bartram C et al. (1993) McArdle's disease: a nonsense mutation in exon 1 of the muscle glycogen phosphorylase gene explains some but not all cases. Hum Mol Genet 2: 1291–1293
Aquaron R et al. (2007) Molecular characterization of myophosphorylase deficiency (McArdle disease) in 34 patients from Southern France: identification of 10 new mutations: absence of genotype-phenotype correlation. Neuromuscul Disord 17: 235–241
Deschauer M et al. (2007) Analysis of spectrum and frequencies of mutations in McArdle disease: identification of 13 novel mutations. J Neurol 254: 797–802
Martin MA et al. (2000) Molecular heterogeneity of myophosphorylase deficiency (McArdle's disease): a genotype-phenotype correlation study. Ann Neurol 50: 574–581
Rubio JC et al. (2006) A proposed molecular diagnostic flowchart for myophosphorylase deficiency (McArdle disease) in blood samples from Spanish patients. Hum Mutat 28: 203–204
Tsujino S et al. (1994) Three new mutations in patients with myophosphorylase deficiency (McArdle disease). Am J Hum Genet 54: 44–52
Fernandez R et al. (2000) A novel missense mutation (W797R) in the myophosphorylase gene in Spanish patients with McArdle disease. Arch Neurol 57: 217–219
Bruno C et al. (1999). Molecular characterization of McArdle's disease in two large Finnish families. J Neurol Sci 165: 121–125
Fernandez-Cadenas I et al. (2003) Splicing mosaic of the myophosphorylase gene due to a silent mutation in McArdle disease. Neurology 61: 1432–1434
García-Consuegra I et al.: Novel mutations in patients with McArdle disease by analysis of skeletal muscle mRNA. J Med Genet, in press
Pari G et al. (1999) Myophosphorylase gene transfer in McArdle's disease myoblasts in vitro. Neurology 53: 1352–1354
Howell JM et al. (2008) Adenovirus and adeno-associated virus-mediated delivery of human myophosphorylase cDNA and LacZ cDNA to muscle in the ovine model of McArdle's disease: expression and re-expression of glycogen phosphorylase. Neuromuscul Disord 18: 248–258
Nogales-Gadea G et al. (2008) Expression of the muscle glycogen phosphorylase gene in patients with McArdle disease: the role of nonsense-mediated mRNA decay. Hum Mutat 29: 277–283
Welch EM et al. (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447: 87–91
Schroers A et al. (2006). Gentamicin treatment in McArdle disease: failure to correct myophosphorylase deficienc. Neurology 66: 285–286
Martinuzzi A et al. (2008) Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease. Muscle Nerve 37: 350–357
Poels PJ et al. (1990) Dantrolene sodium does influence the second-wind phenomenon in McArdle's disease: electrophysiological evidence during exercise in a double-blind placebo-controlled, cross-over study in 5 patients. J Neurol Sci 100: 108–112
Steele IC et al. (1996) A double blind, placebo controlled, cross over trial of D-ribose in McArdle disease. J Neurol Sci 136: 174–177
Vorgerd M et al. (2002) Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial. Arch Neurol 57: 956–963
Vorgerd M et al. (2002) Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: double-blind, placebo-controlled crossover study. Arch Neurol 59: 97–101
Andersen ST and Vissing J (2008) Carbohydrate- and protein-rich diets in McArdle disease: effects on exercise capacity. J Neurol Neurosurg Psychiatry [10.1136/jnnp.2008.146548]
MacLean D et al. (1998) Oral branched chain amino acids do not improve exercise capacity in McArdle's disease. Neurology 51: 1456–1459
Andersen ST et al. (2008) Effect of oral sucrose shortly before exercise on work capacity in McArdle disease. Arch Neurol 65: 786–789
Quinlivan R et al. Pharmacological and nutritional treatment for McArdle disease (glycogen storage disease type V). Cochrane Database Systematic Reviews 2008, Issue 1. Art. No.: CD003458. 10.1002/14651858.CD003458.pub3
Jensen KE et al. (1990) Kinetics following high protein diet in McArdle's syndrome: a 31P magnetic resonance spectroscopy study. Acta Neurol Scand 81: 499–503
Slonim AE and Goans PJ (1985) Myopathy in McArdle's syndrome: improvement with a high-protein diet. New Engl J Med 312: 355–359
Kushner RF and Berman SA (1990) Are high protein diets effective in McArdle's disease. Arch Neurol 47: 383–384
Haller RG et al. (2006) Aerobic conditioning: an effective therapy in McArdle's disease. Ann Neurol 59: 922–928
Acknowledgements
Research relating to McArdle disease by A Lucia and M Pérez is supported by the Health Research Fund of the Spanish Ministry of Health (FIS, ref. #PI061183). Research for the Spanish consortium for the study of McArdle disease is supported by the Health Research Fund (FIS, ref. #PI040487, PI041157, PI040362) and the Spanish Centre for Biomedical Network Research on Rare Diseases (CIBERER). Désirée Lie, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the Medscape-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Lucia, A., Nogales-Gadea, G., Pérez, M. et al. McArdle disease: what do neurologists need to know?. Nat Rev Neurol 4, 568–577 (2008). https://doi.org/10.1038/ncpneuro0913
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro0913
- Springer Nature Limited
This article is cited by
-
Developing a diagnostic framework for patients presenting with Exercise Induced Leg Pain (EILP): a scoping review
Journal of Foot and Ankle Research (2023)
-
Glycogen storage diseases
Nature Reviews Disease Primers (2023)
-
Data from the European registry for patients with McArdle disease (EUROMAC): functional status and social participation
Orphanet Journal of Rare Diseases (2023)
-
An elderly diabetic patient with McArdle disease and recurrent rhabdomyolysis: a potential association with late hypoinsulinemia?
BMC Geriatrics (2020)
-
Creation and implementation of a European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC registry)
Orphanet Journal of Rare Diseases (2020)